EBITDA: Income before interest, taxes, depreciation and amortization.
Vaxcyte, Inc. (PCVX) had EBITDA of $-492.64M for the most recently reported fiscal year, ending 2023-12-31.
Income Statement Financials | |
-- |
|
$-402.27M |
|
-- |
|
-- |
|
$468.04M |
|
$-468.04M |
|
$65.78M |
|
$-402.27M |
|
$-402.27M |
|
$-402.27M |
|
$-402.27M |
|
$-402.27M |
|
$-402.27M |
|
$-468.04M |
|
EBITDA |
$-492.64M |
97.16M |
|
97.16M |
|
$-4.14 |
|
$-4.14 |
|
Balance Sheet Financials | |
$1.10B |
|
$79.63M |
|
$311.96M |
|
$1.41B |
|
$145.34M |
|
-- |
|
$22.11M |
|
$167.45M |
|
$1.24B |
|
$1.24B |
|
$1.24B |
|
95.36M |
|
Cash Flow Statement Financials | |
$-296.79M |
|
$-773.31M |
|
$639.81M |
|
$835.53M |
|
$398.55M |
|
$-436.97M |
|
$48.76M |
|
-- |
|
-- |
|
Fundamental Metrics & Ratios | |
7.54 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-312.85M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-32.43% |
|
-32.43% |
|
-28.57% |
|
-32.43% |
|
$13.01 |
|
$-3.22 |
|
$-3.05 |